LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
540
via seekingalpha.comBusiness & Companies

GSK wins FDA accelerated approval for neladalkib, a lung cancer therapy from the Nuvalent acquisition

FROM THE WIRE · SEEKINGALPHA.COM

[GSK -Glaxosmithkline headquarters office building in Poznan.] Magdalena Wygralak The U.S. Food and Drug Administration on Tuesday granted accelerated approval to neladalkib, a lung cancer therapy now owned by GSK (GSK [https://seekingalpha.com/symbol/GSK]), following its $10.6B…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe early approval strengthens GSK's oncology pipeline following its $10.6 billion acquisition of Nuvalent.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The FDA granted accelerated approval to neladalkib, a kinase inhibitor.
  2. 02The approval covers adults with locally advanced or metastatic non-small cell lung cancer, as a late-line option.
  3. 03The decision came ahead of the November 27 target action date set for Nuvalent's application.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.